Your session is about to expire
← Back to Search
Imlifidase for Kidney Transplant Rejection
Study Summary
This trial is investigating whether imlifidase is more efficient than plasma exchange at reducing DSA in patients with active or chronic active AMR after a kidney transplant.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 15 Patients • NCT03157037Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the participant recruitment rate for this research project?
"Currently, enrolment for this medical trial is closed; it was first published on April 30th 2019 and last updated November 16th 2022. However, there are currently 30 clinical trials enrolling patients with rejection; transplant kidney issues as well as 5 studies in need of participants studying Imlifidase."
Is Imlifidase an acceptable risk for patients considering its therapeutic effects?
"While there is evidence of Imlifidase's safety, its efficacy still needs to be evaluated. Consequently, we have assigned it a score of 2 on our scale from 1-3."
Is there capacity for additional participants in this research endeavor?
"This particular study, posted on April 30th 2019 and last updated November 16th 2022, is not currently enrolling patients. However, 35 other clinical trials are actively recruiting participants for their research studies."
Have any additional experiments been conducted surrounding Imlifidase?
"At present, 5 trials exploring Imlifidase are live with 1 in Phase 3. These clinical studies have 37 locations spread across the United States, most notably New york City."
What clinical conditions is Imlifidase typically administered for?
"Imlifidase has been demonstrated to be a useful intervention for desensitizing kidneys prior to transplantation."
What is the current geographic scope of this research endeavor?
"This clinical trial is being hosted at the Brigham and Women Hospital in Boston, Mayo Clinic in Rochester, and Cedars-Sinai Medical Center in Los Angeles. Additionally it will be conducted out of 4 other medical sites as well."
Share this study with friends
Copy Link
Messenger